Pulsenmore Ltd. Ordinary Shares

Pulsenmore Strengthens U.S. Commercial Leadership, Appoints Med-Tech Veteran David Woods as Chief Commercial Officer

Pulsenmore appointed medtech veteran David Woods as Chief Commercial Officer and is expanding its U.S. commercial team as it scales stateside operations. Woods brings 25+ years of medtech experience, most recently as CCO of Creo Medical and previously President and CEO of PENTAX Medical Americas. The hire follows FDA De Novo authorization of the company's home prenatal ultrasound system and a strategic collaboration with Ouma Health; Pulsenmore is also exploring opportunities tied to the federal Rural Health Transformation Program.

•19d ago

Pulsenmore Expands Its Fertility Platform into the UK

Pulsenmore completed registration of its Pulsenmore FC home ultrasound system with the UK's MHRA, allowing it to be marketed across the United Kingdom and Northern Ireland. The clearance follows the system's recent European registration under the MDR and represents the company's expansion from pregnancy monitoring into fertility care. Pulsenmore FC enables women undergoing IVF and fertility preservation to perform vaginal ultrasound scans at home to monitor follicular development and endometrial thickness under remote clinical guidance, reducing repeated clinic visits. It is the company's second product to reach international markets. Citing HFEA data, the company sizes the UK opportunity at more than 100,000 fertility treatment and storage cycles in 2024, with roughly 53,000 IVF patients and 21,400 IVF births, or 3.2% of all UK births. Management said it intends to extend Pulsenmore FC into additional countries with significant IVF and fertility preservation cycles, though no UK commercial agreements, pricing, or adoption timelines were disclosed in the release.

•1mo ago

Pulsenmore Expands into Fertility Care: Completes CE European Registration of Home Ultrasound System for Follicular Monitoring

Pulsenmore completed the CE European registration process under the Medical Device Regulation (MDR) for Pulsenmore FC, a home ultrasound system for monitoring follicular development and endometrial thickness during IVF and fertility preservation treatments, enabling marketing and sales across European markets. It is the company's second product authorized in Europe and its first expansion beyond prenatal care into the broader women's health market. The release cites ESHRE data showing more than 1.15 million assisted reproduction treatment cycles reported across Europe in 2023, more than half involving ovarian stimulation requiring repeated ultrasound monitoring. Clinical support comes from a Rabin Medical Center study published in JMIR showing high agreement between home scans and in-clinic exams. In Israel, the system has Ministry of Health approval and a January 2026 commercial agreement with Clalit Health Services, though no European commercial partnerships have yet been announced. Founder and CEO Dr. Elazar Sonnenschein framed the registration as Pulsenmore's evolution from a single-product prenatal company toward a broader home ultrasound platform for women's health.

•1mo ago

Pulsenmore Ltd. Announces Financial Results and Business Highlights for the First Half of 2026

Pulsenmore reported H1 2026 revenue of NIS 6.1 million, up 53% year-over-year, driven by increased sales to Clalit Health Services and the initial launch of U.S. commercial operations following FDA authorization. Operational highlights included the first U.S. commercial agreements and patient scans, a strategic partnership with Ouma Health, and the receipt of NIS 5 million in AI innovation grants from the Israel Innovation Authority. The company closed a private placement raising NIS 22.5 million in gross proceeds and ended the period with NIS 70 million in cash, while recording a net loss of NIS 35 million due to expanded commercialization efforts and financial expenses related to warrants.

•2mo ago

Pulsenmore Expands Its Home Ultrasound Activity in Israel: Ichilov Adopts the Technology, Expanding Access to At-Home Pregnancy Monitoring

Pulsenmore announced the integration of its home ultrasound technology at Lis Maternity and Women's Hospital at Ichilov, a major center for women's care in Israel. This adoption expands the company's presence in central Israel and broadens the availability of its hybrid monitoring model, which combines hospital visits with at-home scans. The company currently operates three care models in Israel, including a nationwide service supported by Clalit Health Services and a Hospital at Home model.

•2mo ago

Pulsenmore Receives Second AI Grant Within One Month: Israel Innovation Authority Approves $1.27 Million for SmartScan AI Program

Pulsenmore secured a $1.27 million grant from the Israel Innovation Authority for its SmartScan AI R&D program, marking its second AI grant in a month. The total non-dilutive funding for AI initiatives now stands at approximately $1.6 million, backing a combined program scope of about $3.12 million. SmartScan AI aims to use real-time feedback to guide users during home ultrasound scans, leveraging data from over 250,000 clinical scans to reduce operator dependency.

•2mo ago

Pulsenmore Selected for Israel Innovation Authority and Ministry of Health Program to Lead an $1 Million AI Development Project

Pulsenmore was selected for Israel's Healthcare AI Regulatory Sandbox Program, securing funding to develop AI applications for its home ultrasound platform. The project aims to automate the identification of key ultrasound parameters to streamline clinical workflows and reduce physician review time. Pulsenmore will collaborate with Beilinson Hospital and Clalit Health Services, leveraging a dataset of over 250,000 scans for clinical validation.

•3mo ago

Pulsenmore Announces Strategic Partnership with Ouma Health to Expand Access to Remote Prenatal Care Across the United States

Pulsenmore partnered with Ouma Health to integrate its FDA-authorized home ultrasound platform into Ouma's virtual maternity care model across the U.S. The collaboration enables clinicians to extend prenatal monitoring into patients' homes and represents a significant expansion of Pulsenmore's presence in the U.S. maternal health market. Management highlighted that the partnership addresses access gaps in maternal care deserts, with 35% of U.S. counties lacking adequate services.

•4mo ago